A role for cannabinoid CB1 receptors in mood and anxiety disorders - PubMed (original) (raw)
Review
A role for cannabinoid CB1 receptors in mood and anxiety disorders
J M Witkin et al. Behav Pharmacol. 2005 Sep.
Abstract
Mood and anxiety disorders, the most prevalent of the psychiatric disorders, cause immeasurable suffering worldwide. Despite impressive advances in pharmacological therapies, improvements in efficacy and side-effect profiles are needed. The present literature review examines the role that the endocannabinoid system may play in these disorders and the potential value of targeting this system in the search for novel and improved medications. Cannabis and its major psychoactive component (-)-trans-delta9-tetrahydrocannabinol, have profound effects on mood and can modulate anxiety and mood states. Cannabinoid receptors and other protein targets in the central nervous system (CNS) that modulate endocannabinoid function have been described. The discovery of selective modulators of some of these sites that increase or decrease endocannabinoid neurotransmission, primarily through the most prominent of the cannabinoid receptors in the CNS, the CB1 receptors, combined with transgenic mouse technology, has enabled detailed investigations into the role of these CNS sites in the regulation of mood and anxiety states. Although data point to the involvement of the endocannabinoid system in anxiety states, the pharmacological evidence seems contradictory: both anxiolytic- and anxiogenic-like effects have been reported with both endocannabinoid neurotransmission enhancers and blockers. Due to advances in the development of selective compounds directed at the CB1 receptors, significant progress has been made on this target. Recent biochemical and behavioural findings have demonstrated that blockade of CB1 receptors engenders antidepressant-like neurochemical changes (increases in extracellular levels of monoamines in cortical but not subcortical brain regions) and behavioural effects consistent with antidepressant/antistress activity in rodents.
Similar articles
- Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
Moreira FA, Grieb M, Lutz B. Moreira FA, et al. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44. doi: 10.1016/j.beem.2008.09.003. Best Pract Res Clin Endocrinol Metab. 2009. PMID: 19285266 Review. - [Functional role of the endocannabinoid system in emotional homeostasis].
Marco EM, Viveros MP. Marco EM, et al. Rev Neurol. 2009 Jan 1-15;48(1):20-6. Rev Neurol. 2009. PMID: 19145562 Review. Spanish. - The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB. Xie S, et al. J Clin Pharm Ther. 2007 Jun;32(3):209-31. doi: 10.1111/j.1365-2710.2007.00817.x. J Clin Pharm Ther. 2007. PMID: 17489873 Review. - Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice.
Balerio GN, Aso E, Maldonado R. Balerio GN, et al. Psychopharmacology (Berl). 2006 Mar;184(3-4):504-13. doi: 10.1007/s00213-005-0251-9. Epub 2006 Jan 14. Psychopharmacology (Berl). 2006. PMID: 16416159 - Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine.
Guidali C, ViganĂ² D, Petrosino S, Zamberletti E, Realini N, Binelli G, Rubino T, Di Marzo V, Parolaro D. Guidali C, et al. Int J Neuropsychopharmacol. 2011 Feb;14(1):17-28. doi: 10.1017/S1461145710000209. Epub 2010 Mar 3. Int J Neuropsychopharmacol. 2011. PMID: 20196921
Cited by
- Altering endocannabinoid neurotransmission at critical developmental ages: impact on rodent emotionality and cognitive performance.
Trezza V, Campolongo P, Manduca A, Morena M, Palmery M, Vanderschuren LJ, Cuomo V. Trezza V, et al. Front Behav Neurosci. 2012 Jan 24;6:2. doi: 10.3389/fnbeh.2012.00002. eCollection 2012. Front Behav Neurosci. 2012. PMID: 22291624 Free PMC article. - Alternatives to atypical antipsychotics for the management of dementia-related agitation.
Passmore MJ, Gardner DM, Polak Y, Rabheru K. Passmore MJ, et al. Drugs Aging. 2008;25(5):381-98. doi: 10.2165/00002512-200825050-00003. Drugs Aging. 2008. PMID: 18447403 Review. - Characterization of novel cannabinoid based T-type calcium channel blockers with analgesic effects.
Bladen C, McDaniel SW, Gadotti VM, Petrov RR, Berger ND, Diaz P, Zamponi GW. Bladen C, et al. ACS Chem Neurosci. 2015 Feb 18;6(2):277-87. doi: 10.1021/cn500206a. Epub 2014 Nov 5. ACS Chem Neurosci. 2015. PMID: 25314588 Free PMC article. - Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.
Scavone JL, Sterling RC, Van Bockstaele EJ. Scavone JL, et al. Neuroscience. 2013 Sep 17;248:637-54. doi: 10.1016/j.neuroscience.2013.04.034. Epub 2013 Apr 24. Neuroscience. 2013. PMID: 23624062 Free PMC article. Review. - Cannabinoid modulation of amygdala reactivity to social signals of threat in humans.
Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H. Phan KL, et al. J Neurosci. 2008 Mar 5;28(10):2313-9. doi: 10.1523/JNEUROSCI.5603-07.2008. J Neurosci. 2008. PMID: 18322078 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical